为评估磁共振引导下聚焦超声治疗非腹部腹内腹外腹腔间隔瘤的安全性和疗效，三个中心共对105名腹腔间隔瘤纤维瘤患者（79名女性，26名男性，年龄为35±14岁）进行了磁共振引导下聚焦超声治疗（2011年至2021年）。在治疗后的随访最后，评估了患者的总肿瘤和活力肿瘤情况。使用（改进的）实体肿瘤响应评估标准（RECIST v.1.1和mRECIST）评估了反应和无进展生存期（PFS）。比较了数字评分表（NRS）疼痛和36项简式健康调查问卷（SF-36）得分的变化。记录了与治疗相关的不良事件。初始肿瘤容积的中位数为114 mL（IQR 314 mL）。经过磁共振引导下聚焦超声治疗后，中位数的总肿瘤和活力肿瘤容积分别减少到51 mL（95% CI：30-71 mL，n = 101，p < 0.0001）和29 mL（95% CI：17-57 mL，n = 88，p < 0.0001），在随访的最后时间点（中位数：15个月，95% CI：11-20个月）。根据总肿瘤测量（RECIST），86%（95% CI：75-93%）在最后的随访中至少有稳定疾病或更好的结果，但50%（95% CI：38-62%）的活力结节（mRECIST）在肿瘤内继续进展。总肿瘤和活力肿瘤的中位无进展生存期分别为17个月和13个月。NRS评分从6（IQR 3）下降到3（IQR 4）（p < 0.001）。SF-36得分改善（身体健康：41（IQR 15）增至46（IQR 12）；p = 0.05；心理健康：49（IQR 17）增至53（IQR 9）；p = 0.02）。并发症发生率为36%，最常见的是一度/二度皮肤烧伤。磁共振引导下聚焦超声治疗在这105例非腹部腹内腹腔间隔瘤患者中减小了肿瘤体积，减轻了疼痛，并改善了生活质量。成像引导下的消融术逐渐成为除手术、放疗和药物治疗以外治疗腹腔间隔瘤纤维瘤的替代方法。磁共振引导下高强度集中超声是一种无切口的消融技术，可以有效安全地减轻肿瘤负担。• 用磁共振引导下高强度集中超声治疗105例腹腔间隔瘤纤维瘤患者。• 磁共振引导下聚焦超声消融降低了肿瘤体积和疼痛，提高了生活质量。• 磁共振引导下聚焦超声是治疗非腹部腹内腹腔间隔瘤患者的选项。©2023。作者授予 European Society of Radiology 独家许可。

To assess the safety and efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment extra-abdominal desmoids.A total of 105 patients with desmoid fibromatosis (79 females, 26 males; 35 ± 14 years) were treated with MRgFUS between 2011 and 2021 in three centers. Total and viable tumors were evaluated per patient at last follow-up after treatment. Response and progression-free survival (PFS) were assessed with (modified) response evaluation criteria in solid tumors (RECIST v.1.1 and mRECIST). Change in Numerical Rating Scale (NRS) pain and 36-item Short Form Health Survey (SF-36) scores were compared. Treatment-related adverse events were recorded.The median initial tumor volume was 114 mL (IQR 314 mL). After MRgFUS, median total and viable tumor volume decreased to 51 mL (95% CI: 30-71 mL, n = 101, p < 0.0001) and 29 mL (95% CI: 17-57 mL, n = 88, p < 0.0001), respectively, at last follow-up (median: 15 months, 95% CI: 11-20 months). Based on total tumor measurements (RECIST), 86% (95% CI: 75-93%) had at least stable disease or better at last follow-up, but 50% (95% CI: 38-62%) of remaining viable nodules (mRECIST) progressed within the tumor. Median PFS was reached at 17 and 13 months for total and viable tumors, respectively. NRS decreased from 6 (IQR 3) to 3 (IQR 4) (p < 0.001). SF-36 scores improved (physical health (41 (IQR 15) to 46 (IQR 12); p = 0.05, and mental health (49 (IQR 17) to 53 (IQR 9); p = 0.02)). Complications occurred in 36%, most commonly 1st/2nd degree skin burns.MRgFUS reduced tumor volume, reduced pain, and improved quality of life in this series of 105 patients with extra-abdominal desmoid fibromatosis.Imaging-guided ablation is being increasingly used as an alternative to surgery, radiation, and medical therapy for the treatment of desmoid fibromatosis. MR-guided high-intensity focused ultrasound is an incisionless ablation technique that can be used to reduce tumor burden effectively and safely.• Desmoid fibromatosis was treated with MR-guided high-intensity focused ultrasound in 105 patients. • MR-guided focused ultrasound ablation reduced tumor volume and pain and improved quality of life. • MR-guided focused ultrasound is a treatment option for patients with extra-abdominal desmoid tumors.© 2023. The Author(s), under exclusive licence to European Society of Radiology.